D
Daniele Roberto Giacobbe
Researcher at University of Genoa
Publications - 236
Citations - 6785
Daniele Roberto Giacobbe is an academic researcher from University of Genoa. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 29, co-authored 176 publications receiving 3710 citations.
Papers
More filters
Journal ArticleDOI
International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP).
Brian T. Tsuji,Jason M. Pogue,Alexandre P. Zavascki,Mical Paul,Mical Paul,George L. Daikos,Alan Forrest,Daniele Roberto Giacobbe,Claudio Viscoli,Helen Giamarellou,Ilias Karaiskos,Donald Kaye,Johan W. Mouton,Vincent H. Tam,Visanu Thamlikitkul,Richard G. Wunderink,Jian Li,Roger L. Nation,Keith S Kaye +18 more
TL;DR: In this paper, the authors report consensus therapeutic guidelines for agent selection and dosing of colistin and polymyxin antibiotics for optimal use in adult patients, as endorsed by the American College of Clinical Pharmacy (ACCP), Infectious Diseases Society of America (IDSA), International Society of Anti-Infective Pharmacology (ISAP), Society for Critical Care Medicine (SCCM), and Society of Infectious diseases Pharmacists (SIDP).
Journal ArticleDOI
Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study
Mario Tumbarello,Enrico Maria Trecarichi,Francesco Giuseppe De Rosa,Maddalena Giannella,Daniele Roberto Giacobbe,Matteo Bassetti,Angela Raffaella Losito,Michele Bartoletti,Valerio Del Bono,Silvia Corcione,G. Maiuro,Sara K. Tedeschi,Luigi Celani,Chiara Simona Cardellino,Teresa Spanu,Anna Marchese,Simone Ambretti,Roberto Cauda,Claudio Viscoli,Pierluigi Viale +19 more
TL;DR: KPC-Kp infections are associated with high mortality and treatment with two or more drugs displaying activity against the isolate improves survival, mainly in patients who are critically ill.
Journal ArticleDOI
The novel Chinese coronavirus (2019-nCoV) infections: Challenges for fighting the storm.
TL;DR: It has been confirmed that the disease is caused by a novel coronavirus (provisionally named 2019-nCoV) and the case rate fatality is 2.2% (170/7824).
Journal ArticleDOI
Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion.
Paul E. Verweij,Bart J. A. Rijnders,Roger J. M. Brüggemann,Elie Azoulay,Matteo Bassetti,Stijn Blot,Stijn Blot,Thierry Calandra,Cornelius J. Clancy,Cornelius J. Clancy,Oliver A. Cornely,Tom Chiller,Pieter Depuydt,Daniele Roberto Giacobbe,Nico A F Janssen,Bart Jan Kullberg,Katrien Lagrou,Cornelia Lass-Flörl,Russell E. Lewis,Peter Wei Lun Liu,Olivier Lortholary,Olivier Lortholary,Johan Maertens,Ignacio Martin-Loeches,M. Hong Nguyen,M. Hong Nguyen,Thomas F. Patterson,Thomas R. Rogers,Jeroen Schouten,Isabel Spriet,Lore Vanderbeke,Joost Wauters,Frank L. van de Veerdonk +32 more
TL;DR: The IAPA case definitions may be useful to classify patients with COVID-19-associated pulmonary aspergillosis (CAPA), while awaiting further studies that provide more insight into the interaction between Aspergillus and the SARS-CoV-2-infected lung.
Journal ArticleDOI
Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by Klebsiella pneumoniae Carbapenemase-producing K. pneumoniae.
Mario Tumbarello,Enrico Maria Trecarichi,Alberto Corona,Francesco Giuseppe De Rosa,Matteo Bassetti,Cristina Mussini,Francesco Menichetti,Claudio Viscoli,Caterina Campoli,Mario Venditti,Andrea De Gasperi,Alessandra Mularoni,Carlo Tascini,Giustino Parruti,Carlo Pallotto,Simona Sica,Ercole Concia,Rosario Cultrera,Gennaro De Pascale,Alessandro Capone,Spinello Antinori,Silvia Corcione,Elda Righi,Angela Raffaella Losito,Margherita Digaetano,Francesco Amadori,Daniele Roberto Giacobbe,Giancarlo Ceccarelli,E. Mazza,Francesca Raffaelli,Teresa Spanu,Roberto Cauda,Pierluigi Viale +32 more
TL;DR: CAZ-AVI appears to be a promising drug for treatment of severe KPC-Kp infections, especially those involving bacteremia, as well as hospital-acquired pneumonia, and for gram-negative infections with limited treatment options.